6611 - 6620 of 8620 Results
Title
Year
- Invariable Ribosome Stoichiometry During Murine Erythroid Differentiation: Implications for Understanding Ribosomopathies2022OPENTitle: Invariable Ribosome Stoichiometry During Murine Erythroid Differentiation: Implications for Understanding RibosomopathiesJournal Name: Frontiers in Molecular BiosciencesPublisher: Frontiers Media SAVol: 9Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fmolb.2022.805541Best OA location URL: https://doi.org/10.3389/fmolb.2022.805541Citation Count: 4
-
OPENTitle: Editorial: Digital Innovation and Data-Driven Research in Neurodegenerative DiseasesJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.961847Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.961847/pdfCitation Count: 0
- The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II2022OPENTitle: The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and IIJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.994114Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.994114/pdfCitation Count: 4
- Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia2022OPENTitle: Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesiaJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.846126Best OA location URL: https://doi.org/10.3389/fneur.2022.846126Citation Count: 5
- Adjuvant medical therapy in cervical dystonia after deep brain stimulation: A retrospective analysis2022OPENTitle: Adjuvant medical therapy in cervical dystonia after deep brain stimulation: A retrospective analysisJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.927573Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.927573/pdfCitation Count: 3
- Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis2022OPENTitle: Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosisJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.919778Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.919778/pdfCitation Count: 9
- OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE2022OPENTitle: OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBEJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.914486Best OA location URL: https://doi.org/10.3389/fneur.2022.914486Citation Count: 7
- Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study2022OPENTitle: Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.773999Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.773999/pdfCitation Count: 10
- The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program2022OPENTitle: The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development programJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.1036068Best OA location URL: https://doi.org/10.3389/fneur.2022.1036068Citation Count: 19
- Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson’s disease2022OPENTitle: Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson’s diseaseJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 14Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2022.1061096Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnagi.2022.1061096/pdfCitation Count: 8